MPAN (Mitochondrial Membrane Protein-Associated Neurodegeneration, Mitochondrial CoA Synthesis Dysfunction) is the third most common NBIA disorder, caused by autosomal recessive mutations in the COASY gene (coenzyme A synthetase) or less commonly MTOR. The disorder presents in adolescence or early adulthood with progressive dystonia, parkinsonism, and cognitive decline. MPAN is distinguished by mitochondrial respiratory chain dysfunction and iron-sulfur cluster assembly defects alongside the characteristic brain iron accumulation@dusi2022.
| Feature | Detail |
|---|---|
| Gene | COASY (coenzyme A synthetase) |
| Inheritance | Autosomal recessive |
| Mechanism | Loss-of-function mutations |
| Allelic disorder | DOORS syndrome (some COASY variants) |
| Protein | CoA synthetase (bifunctional enzyme: pantothenate kinase + CoA synthetase domains) |
COASY encodes a bifunctional enzyme that catalyzes the final two steps of coenzyme A biosynthesis: (1) conversion of phosphopantetheine to dephospho-CoA, and (2) ATP-dependent phosphorylation of dephospho-CoA to CoA@dusi2022. Unlike PANK2 (which catalyzes step 1), COASY mutations cause deficiency in the final step of the pathway, creating a distinct biochemical phenotype from PKAN.
CoA is essential for:
The COASY enzyme catalyzes the final step of CoA biosynthesis, making it indispensable for cellular CoA homeostasis. Loss of function causes 30-70% reduction in cellular CoA depending on tissue@dusi2022.
CoA deficiency impairs:
Iron-sulfur (Fe-S) clusters are essential cofactors for:
CoA deficiency disrupts the mitochondrial Fe-S cluster assembly machinery. This explains why MPAN has more prominent mitochondrial dysfunction than PKAN, and why neurons with high metabolic demands are preferentially affected.
| Feature | MPAN Characteristics |
|---|---|
| Age of onset | Adolescence (10-20 years), occasionally earlier or later |
| Initial symptoms | Gait difficulties, dystonia, clumsiness |
| Core phenotype | Dystonia-parkinsonism (often mixed) |
| Progression | Slowly progressive over decades |
| Cognitive decline | Variable, typically mild-to-moderate |
| Psychiatric symptoms | Common (personality change, depression, OCD features) |
| MRI "eye of the tiger" | Rare or absent (unlike PKAN) |
| Optic atrophy | May occur |
| Seizures | Less common than in BPAN |
| Finding | MPAN Specifics |
|---|---|
| Iron accumulation | Globus pallidus and substantia nigra (SN) |
| Eye of the tiger sign | Usually absent or mild |
| T2 signal changes | SWI hypointensity in GP/SN |
| White matter changes | May be present |
| Atrophy | Progressive caudate and putaminal atrophy |
| Approach | Status | Evidence |
|---|---|---|
| CoA supplementation | Theoretical | CoA crosses BBB poorly; pantetheine/pantethine more viable |
| Pantethine (vitamin B5 derivative) | Experimental | Bypasses PANK2 defect; may partially compensate for COASY loss |
| Iron chelation | Case-by-case | If iron-mediated toxicity predominates |
| DBS (deep brain stimulation) | Used for dystonia | Case reports show benefit for severe dystonia |
| Physical/occupational therapy | Supportive | Maintains function |
| Psychiatric management | Symptomatic | SSRI/SNRI for depression/anxiety |